Does cardiac resynchronization therapy reduce mortality and heart failure hospitalizations in adults with heart failure and LVEF ≤0.40?
Cardiac resynchronization therapy reduces all-cause mortality and heart failure hospitalizations in patients with reduced ejection fraction, regardless of whether they have advanced or less symptomatic disease.
BACKGROUND: Cardiac resynchronization therapy (CRT) reduces morbidity and mortality in patients with advanced symptoms of heart failure. PURPOSE: To assess the benefits and harms of CRT in patients with advanced heart failure and those with less symptomatic disease. DATA SOURCES: A search of electronic databases (1950 to December 2010), hand-searching of reference lists, and unpublished data from principal investigators. Searches were not limited to the English language. STUDY SELECTION: Randomized, controlled trials of CRT compared with usual care and right or left ventricular pacing in adults with heart failure and a left ventricular ejection fraction of 0.40 or less. DATA EXTRACTION: Two reviewers performed independent study selection, data abstraction, and quality assessment by using the Cochrane tool for assessing risk for bias. DATA SYNTHESIS: There were 9082 patients in 25 trials. In patients with New York Heart Association (NYHA) class I and II symptoms, CRT reduced all-cause mortality (6 trials, 4572 participants; risk ratio RR, 0.83 95% CI, 0.72 to 0.96) and heart failure hospitalizations (4 trials, 4349 participants; RR, 0.71 CI, 0.57 to 0.87) without improving functional outcomes or quality of life. In patients with NYHA class III or IV symptoms, CRT improved functional outcomes and reduced both all-cause mortality (19 trials, 4510 participants; RR, 0.78 CI, 0.67 to 0.91) and heart failure hospitalizations (11 trials, 2663 participants; RR, 0.65 CI, 0.50 to 0.86). The implant success rate was 94.4%; peri-implantation deaths occurred in 0.3% of trial participants, mechanical complications in 3.2%, lead problems in 6.2%, and infections in 1.4%. LIMITATION: Subgroup analyses were underpowered and lack data for persons with NYHA class I symptoms, atrial fibrillation, chronic kidney disease, or right bundle branch block. CONCLUSION: Cardiac resynchronization therapy is beneficial for patients with reduced left ventricular ejection fraction, symptoms of heart failure, and prolonged QRS, regardless of NYHA class. PRIMARY FUNDING SOURCE: None.
Al-Majed et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: